China and India emerged as the best outsourcing pharmaceutical destination followed by Korea and Taiwan, according to a study by PriceWaterhouseCoopers on the changing dynamics of pharma outsourcing
to Asia.
China and India's advantages such as lower costs and greater market opportunity outweigh the higher risk compared with the more established and mature regulatory regimes of Australia, Japan and Singapore.
